Complaint Granted In Novartis Bone Drug Case

Law360, New York (April 24, 2007, 12:00 AM EDT) -- Despite objections by Novartis Pharmaceutical Corp., a district court has allowed plaintiffs who allege the pharmaceutical giant’s bone cancer drugs cause jawbone decay to divide into a proposed class seeking dental monitoring and a group seeking personal injury damages, the plaintiffs’ lawyer said Tuesday.

The plaintiffs claim that Novartis drug Aredia and its successor, Zometa, cause osteonecrosis of the jaw. They sought to amend their complaint for the fourth time to include a proposed class of people allegedly at risk for the bone disease seeking dental...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.